Pruvanserin

Pruvanserin is a drug that was under development by Eisai for the treatment of insomnia. It acts as a selective 5-HT2A antagonist. The development was discontinued after unsuccessful phase II clinical trials.

History

Pruvanserin was first developed by the Japanese pharmaceutical company Eisai. The drug was intended to treat insomnia, a sleep disorder that can cause a variety of health problems, including decreased quality of life, increased risk of accidents, and various mental health issues.

The drug works by selectively antagonizing the 5-HT2A receptor. This receptor is one of the several receptors that serotonin binds to. By blocking this receptor, pruvanserin was expected to help regulate sleep patterns and improve sleep quality.

However, the development of pruvanserin was discontinued after phase II clinical trials. The reasons for this are not publicly disclosed, but it is common for drugs to be discontinued at this stage due to lack of efficacy, safety concerns, or strategic reasons.

Mechanism of Action

Pruvanserin works by selectively blocking the 5-HT2A receptor. This receptor is one of the several receptors that serotonin, a neurotransmitter, binds to. By blocking this receptor, pruvanserin was expected to help regulate sleep patterns and improve sleep quality.

Clinical Trials

Pruvanserin underwent phase II clinical trials for the treatment of insomnia. However, the development was discontinued after this stage. The reasons for this are not publicly disclosed, but it is common for drugs to be discontinued at this stage due to lack of efficacy, safety concerns, or strategic reasons.

See Also

• Eisai Co.
• Insomnia
• 5-HT2A receptor

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia